Trials / Conditions / Mast Cell Leukemia

Mast Cell Leukemia

20 registered clinical trials studyying Mast Cell Leukemia — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM NCT04695431	Blueprint Medicines Corporation	—
Terminated	GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies NCT03214666	GT Biopharma, Inc.	Phase 1 / Phase 2
Recruiting	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Bloo NCT03779854	Fred Hutchinson Cancer Center	Phase 2
Completed	(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted NCT03580655	Blueprint Medicines Corporation	Phase 2
Completed	(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory NCT02561988	Blueprint Medicines Corporation	Phase 1
Terminated	Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis NCT02415608	Jason Robert Gotlib	Phase 2
Completed	Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia NCT01807598	Jason Robert Gotlib	Phase 2
Completed	Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Le NCT01869777	Wake Forest University Health Sciences	N/A
Completed	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919	National Cancer Institute (NCI)	Phase 1
Completed	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766	Wake Forest University Health Sciences	Phase 2
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Completed	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494	Wake Forest University Health Sciences	N/A
Completed	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747	National Cancer Institute (NCI)	Phase 1
Terminated	Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426	National Cancer Institute (NCI)	Phase 2
Completed	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352	Fred Hutchinson Cancer Center	Phase 2
Completed	Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With NCT00898079	Children's Oncology Group	—
Completed	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235	Fred Hutchinson Cancer Center	N/A
Completed	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593	Fred Hutchinson Cancer Center	N/A
No Longer Available	Managed Access Programs for PKC412, Midostaurin NCT05219266	Novartis Pharmaceuticals	—